Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

477 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Coadministration of indinavir and nelfinavir in human immunodeficiency virus type 1-infected adults: safety, pharmacokinetics, and antiretroviral activity.
Riddler SA, Havlir D, Squires KE, Kerr B, Lewis RH, Yeh K, Wynne LH, Zhong L, Peng Y, Deutsch P, Saah A. Riddler SA, et al. Among authors: havlir d. Antimicrob Agents Chemother. 2002 Dec;46(12):3877-82. doi: 10.1128/AAC.46.12.3877-3882.2002. Antimicrob Agents Chemother. 2002. PMID: 12435691 Free PMC article. Clinical Trial.
3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine.
Gulick RM, Mellors JW, Havlir D, Eron JJ, Meibohm A, Condra JH, Valentine FT, McMahon D, Gonzalez C, Jonas L, Emini EA, Chodakewitz JA, Isaacs R, Richman DD. Gulick RM, et al. Among authors: havlir d. Ann Intern Med. 2000 Jul 4;133(1):35-9. doi: 10.7326/0003-4819-133-1-200007040-00007. Ann Intern Med. 2000. PMID: 10877738 Clinical Trial.
Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia.
Shulman N, Zolopa A, Havlir D, Hsu A, Renz C, Boller S, Jiang P, Rode R, Gallant J, Race E, Kempf DJ, Sun E. Shulman N, et al. Among authors: havlir d. Antimicrob Agents Chemother. 2002 Dec;46(12):3907-16. doi: 10.1128/AAC.46.12.3907-3916.2002. Antimicrob Agents Chemother. 2002. PMID: 12435695 Free PMC article.
Class-sparing regimens for initial treatment of HIV-1 infection.
Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, Garren KW, George T, Rooney JF, Brizz B, Lalloo UG, Murphy RL, Swindells S, Havlir D, Mellors JW; AIDS Clinical Trials Group Study A5142 Team. Riddler SA, et al. Among authors: havlir d. N Engl J Med. 2008 May 15;358(20):2095-106. doi: 10.1056/NEJMoa074609. N Engl J Med. 2008. PMID: 18480202 Free PMC article. Clinical Trial.
Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment.
Haubrich RH, Riddler SA, DiRienzo AG, Komarow L, Powderly WG, Klingman K, Garren KW, Butcher DL, Rooney JF, Haas DW, Mellors JW, Havlir DV; AIDS Clinical Trials Group (ACTG) A5142 Study Team. Haubrich RH, et al. AIDS. 2009 Jun 1;23(9):1109-18. doi: 10.1097/QAD.0b013e32832b4377. AIDS. 2009. PMID: 19417580 Free PMC article. Clinical Trial.
Failure of initial therapy with two nucleosides and efavirenz is not associated with early emergence of mutations in the C-terminus of HIV-1 reverse transcriptase.
Brehm JH, Lalama CM, Hughes MD, Haubrich R, Riddler SA, Sluis-Cremer N, Mellors JW; AIDS Clinical Trials Group Study A5142 Protocol Team. Brehm JH, et al. J Acquir Immune Defic Syndr. 2011 Apr;56(4):344-8. doi: 10.1097/QAI.0b013e31820cf029. J Acquir Immune Defic Syndr. 2011. PMID: 21350368 Free PMC article.
Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study.
Mugavero MJ, May M, Ribaudo HJ, Gulick RM, Riddler SA, Haubrich R, Napravnik S, Abgrall S, Phillips A, Harris R, Gill MJ, de Wolf F, Hogg R, Günthard HF, Chêne G, D'Arminio Monforte A, Guest JL, Smith C, Murillas J, Berenguer J, Wyen C, Domingo P, Kitahata MM, Sterne JA, Saag MS; AIDS Clinical Trial Group DACS 241 Team; AIDS Clinical Trial Group Study 5095 Team; AIDS Clinical Trial Group Study 5142 team; Antiretroviral Cohort Collaboration. Mugavero MJ, et al. J Acquir Immune Defic Syndr. 2011 Nov 1;58(3):253-60. doi: 10.1097/QAI.0b013e318230372e. J Acquir Immune Defic Syndr. 2011. PMID: 21857357 Free PMC article. Clinical Trial.
Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection.
Haubrich RH, Riddler SA, Ribaudo H, Direnzo G, Klingman KL, Garren KW, Butcher DL, Rooney JF, Havlir DV, Mellors JW; AIDS Clinical Trials Group (ACTG) A5160 and A5142 Study Teams. Haubrich RH, et al. AIDS. 2011 Nov 28;25(18):2269-78. doi: 10.1097/QAD.0b013e32834d0c20. AIDS. 2011. PMID: 21941167 Free PMC article. Clinical Trial.
477 results